Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지
DOI QR코드

DOI QR Code

Responses and adverse effects of carboplatin-based chemotherapy for pediatric intracranial germ cell tumors

  • Ji, Sun-Tae (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Chueh, Hee-Won (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Kim, Ju-Youn (Department of Childrens Cancer Center, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Lim, Su-Jin (Department of Childrens Cancer Center, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Cho, Eun-Joo (Department of Childrens Cancer Center, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Lee, Soo-Hyun (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Yoo, Keon-Hee (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Sung, Ki-Woong (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Koo, Hong-Hoe (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • 투고 : 2010.09.15
  • 심사 : 2010.12.21
  • 발행 : 2011.03.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: Cisplatin-based chemotherapy has been commonly used for the treatment of intracranial germ cell tumors (IC-GCTs). However, this treatment exhibits some adverse effects such as renal problems and hearing difficulty. Carboplatin-based chemotherapy was administered to pediatric patients with IC-GCTs from August 2004 at the Samsung Medical Center. In this study, we assessed the responses and adverse effects of carboplatin-based chemotherapy in pediatric IC-GCTs patients according to the risk group, and compared the results with those of the previous cisplatin-based chemotherapy. Methods: We examined 35 patients (27 men and 8 women) diagnosed with IC-GCTs between August 2004 and April 2008 and received risk-adapted carboplatin-based chemotherapy at the Samsung Medical Center. Patients were divided into either low-risk (LR) or high-risk (HR) groups and a retrospective analysis was performed using information from the medical records. Results: Although hematological complications were common, hearing difficulties or grade 3 or 4 creatinine level elevation were not observed in patients who underwent carboplatin-based chemotherapy. The frequency of febrile neutropenia did not differ between the risk groups. The overall survival was 100% and event-free survival (EFS) was 95.7%. The EFS rate was 100% in the LR group and 90% in the HR group, respectively. Conclusion: Despite their common occurrence in high-risk patients, no lethal hematological complications were associated with carboplatin-based treatment. The current carboplatin-based chemotherapy protocol is safe and effective for the treatment of pediatric patients with IC-GCTs.

키워드

참고문헌

  1. Packer RJ, Cohen BH, Cooney K. Intracranial germ cell tumors. Oncologist 2000;5:312-20.
  2. Cho KT, Wang KC, Kim SK, Shin SH, Chi JG, Cho BK. Pediatric brain tumors: statistics of SNUH, Korea (1959-2000). Childs Nerv Syst 2002;18:30-7. https://doi.org/10.1007/s00381-001-0547-y
  3. Goodwin TL, Sainani K, Fisher PG. Incidence patterns of central nervous system germ cell tumors: a SEER Study. J Pediatr Hematol Oncol 2009;31:541-4. https://doi.org/10.1097/MPH.0b013e3181983af5
  4. Jennings MT, Gelman R, Hochberg F. Intracranial germ-cell tumors: natural history and pathogenesis. J Neurosurg 1985;63:155-67. https://doi.org/10.3171/jns.1985.63.2.0155
  5. Douglas JG, Rockhill JK, Olson JM, Ellenbogen RG, Geyer JR. Cisplatin-based chemotherapy followed by focal, reduced-dose irradiation for pediatric primary central nervous system germinomas. J Pediatr Hematol Oncol 2006;28:36-9.
  6. Kretschmar C, Kleinberg L, Greenberg M, Burger P, Holmes E, Wharam M. Pre-radiation chemotherapy with response-based radiation therapy in children with central nervous system germ cell tumors: a report from the Children's Oncology Group. Pediatr Blood Cancer 2007;48:285-91. https://doi.org/10.1002/pbc.20815
  7. You DK, Lee SH, Yoo KH, Sung KW, Lim DH, Shin HJ, et al. Responses and toxicities of risk-adapted chemotherapy in pediatric intracranial germ cell tumors. Korean J Pediatr 2005;48:186-90.
  8. Yoo KH, Lee SH, Lee J, Sung KW, Jung HL, Koo HH, et al. Improved outcome of central nervous system germ cell tumors: implications for the role of risk-adapted intensive chemotherapy. J Korean Med Sci 2010;25:458-65.
  9. Kellie SJ, Boyce H, Dunkel IJ, Diez B, Rosenblum M, Brualdi L, et al. Primary chemotherapy for intracranial nongerminomatous germ cell tumors: results of the second international CNS germ cell study group protocol. J Clin Oncol 2004;22:846-53. https://doi.org/10.1200/JCO.2004.07.006
  10. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-81. https://doi.org/10.1016/S1053-4296(03)00031-6
  11. Hartmann JT, Lipp HP. Toxicity of platinum compounds. Expert Opin Pharmacother 2003;4:889-901. https://doi.org/10.1517/14656566.4.6.889
  12. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999;17:409-22. https://doi.org/10.1200/JCO.1999.17.1.409
  13. Lokich J, Anderson N. Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol 1998;9:13-21.
  14. Allen JC, DaRosso RC, Donahue B, Nirenberg A. A phase II trial of preirradiation carboplatin in newly diagnosed germinoma of the central nervous system. Cancer 1994;74:940-4. https://doi.org/10.1002/1097-0142(19940801)74:3<940::AID-CNCR2820740323>3.0.CO;2-U
  15. Stern JW, Bunin N. Prospective study of carboplatin-based chemotherapy for pediatric germ cell tumors. Med Pediatr Oncol 2002;39:163-7. https://doi.org/10.1002/mpo.10134
  16. Auletta JJ, O'Riordan MA, Nieder ML. Infections in children with cancer: a continued need for the comprehensive physical examination. J Pediatr Hematol Oncol 1999;21:501-8. https://doi.org/10.1097/00043426-199911000-00010
  17. Castagnola E, Fontana V, Caviglia I, Caruso S, Faraci M, Fioredda F, et al. A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation. Clin Infect Dis 2007;45:1296-304. https://doi.org/10.1086/522533
  18. Hakim H, Flynn PM, Knapp KM, Srivastava DK, Gaur AH. Etiology and clinical course of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol 2009;31:623-9. https://doi.org/10.1097/MPH.0b013e3181b1edc6
  19. Lucas KG, Brown AE, Armstrong D, Chapman D, Heller G. The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis. Cancer 1996;77:791-8. https://doi.org/10.1002/(SICI)1097-0142(19960215)77:4<791::AID-CNCR27>3.0.CO;2-V
  20. Rackoff WR, Gonin R, Robinson C, Kreissman SG, Breitfeld PB. Predicting the risk of bacteremia in childen with fever and neutropenia. J Clin Oncol 1996;14:919-24. https://doi.org/10.1200/JCO.1996.14.3.919
  21. Okamoto H, Watanabe K, Kunikane H, Yokoyama A, Kudoh S, Asakawa T, et al. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer 2007;97:162-9. https://doi.org/10.1038/sj.bjc.6603810

피인용 문헌

  1. Pharmacokinetics, Tissue Distribution, and Plasma Protein Binding Study of Platinum Originating from Dicycloplatin, a Novel Antitumor Supramolecule, in Rats and Dogs by ICP-MS vol.148, pp.2, 2011, https://doi.org/10.1007/s12011-012-9364-2
  2. Recent Advances in Platinum (IV) Complex‐Based Delivery Systems to Improve Platinum (II) Anticancer Therapy vol.35, pp.6, 2011, https://doi.org/10.1002/med.21360